Naperville, IL -- (SBWIRE) -- 07/06/2012 -- Chronic Urticaria or Hives Therapeutics - Pipeline Assessment and Market Forecasts to 2019 report is an essential source of information and analysis on the global Chronic Urticaria Or Hives Therapeutics market. The report identifies the key trends shaping and driving the global Chronic Urticaria Or Hives Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products in the global Chronic Urticaria Or Hives Therapeutics market. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
The report provides information on the key drivers and challenges of the Chronic Urticaria Or Hives Therapeutics market. Its scope includes -
- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) Chronic Urticaria therapeutics market revenue data for 2006–2011, and 2011–2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Chronic Urticaria Or Hives Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Chronic Urticaria Or Hives Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Chronic Urticaria Or Hives Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Chronic Urticaria Or Hives Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Chronic Urticaria Or Hives Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Chronic Urticaria Or Hives Therapeutics market landscape? – Identify, understand and capitalize.
F. Hoffmann-La Roche Ltd. Biofrontera AG (Subsidiary of DNAPrint Genomics, Inc.). Sun Pharmaceutical Industries Limited.
To view table of contents for this market report please visit